Merck Finalizes Nearly $6 Billion Acquisition of Cancer Biotech Terns

Merck has finalized its acquisition of Terns Pharmaceuticals for nearly $6 billion, aiming to boost its cancer drug pipeline following promising clinical data on a bone and blood cancer treatment.

25 Mar, 00:59 — 25 Mar, 13:43

Post Share

Why this matters

This acquisition is significant as it allows Merck to expand its oncology pipeline with new treatments, crucial for its long-term growth as its top-selling cancer drug, Keytruda, approaches patent expiration. It also highlights the ongoing consolidation and strategic investments within the pharmaceutical industry.

Key entitiesMerck Terns Pharmaceuticals Keytruda

The Story

What 10 sources agree on, dispute, and miss

What sources agree on

Merck is acquiring Terns Pharmaceuticals
The acquisition is valued at approximately $6.7 billion
The deal is intended to boost Merck's cancer drug pipeline
Terns Pharmaceuticals is developing an oral treatment for leukemia

Key claims3 agreed · 1 disputed · 1 unverified

✓

Merck is acquiring Terns Pharmaceuticals for $6.7 billion.

agreed·YahoomarketwatchcnbcReutersseeking-alpha

✗

Merck is making a nearly $6 billion deal for Terns.

disputed·wsjFT

Disputed byYahoomarketwatchcnbcReutersseeking-alpha

WSJ and FT report 'nearly $6 billion' while others specify $6.7 billion.

✓

The acquisition is aimed at bulking up Merck's portfolio before Keytruda loses patent protection in 2028.

agreed·cnbcReuters

✓

Terns Pharma shares surged on the news of the buyout deal.

agreed·seeking-alphaFT

The acquisition price is $53 per share.

unverified·seeking-alpha

Coverage gaps

The specific per-share price of the acquisition ($53 per share)

Reportedseeking-alpha

MissingYahoowsjcapital-bg+4

Terns Pharma stock jumped after promising clinical data last year

ReportedFT

MissingYahoowsjcapital-bg+4

The Story

Analyzing sources…

Source Diversity

High (67/100)

10 sources33/33

Spectrum spread— 3/5 buckets covered17/33

Far L

Left2

Left (2)

Yahoocnbc

Center5

Center (5)

bloombergAPmarketwatchReutersFT

Right3

Right (3)

seeking-alphawsjcapital-bg

Far R

Geographic diversity— 4 regions17/34

US7Bulgaria1Intl1UK1

Political spectrum

LeftCenterRight

yahoo

cnbc

marketwatch

reuters

capital-bg

seeking-alpha

wsj

Outlet rating This story

SourceOutletiGeneral editorial lean of the outletStoryiHow they covered this specific storyToneFactuality

Yahoocentercenter-leftneutralMostly Factualstraightforward reporting of financial transaction

cnbccentercenter-leftanalyticalMostly Factualbusiness-oriented, strategic rationale for Merck

Coverage leans: balanced

The coverage is largely factual and business-focused, with a slight emphasis on the financial implications and strategic rationale for Merck, maintaining a balanced political lean.

Sources

Showing 6 of 10 sources

ReutersVery High137d ago

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma - Reuters

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma Reuters

Read full article →

bloombergHigh137d ago

Merck to Buy Terns for $6.7 Billion to Grow in Blood Cancers - Bloomberg.com

Merck to Buy Terns for $6.7 Billion to Grow in Blood Cancers Bloomberg.com

Read full article →

wsjHigh137d ago

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns - WSJ

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns WSJ

Read full article →

FTVery High137d ago

Merck nears $6bn biotech deal to boost cancer drug pipeline

Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year

Read full article →

cnbcMostly Factual137d ago

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

Read full article →

marketwatchMostly Factual137d ago

Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal

Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is developing an oral treatment for leukemia.

By Tomi Kilgore

Read full article →

Coverage Timeline

First report: FT · 25 Mar, 00:59|Full coverage: 10 · 16h|Window: 16h

Left-leaningCenterRight-leaning

FT25 Mar, 00:59First to report

Merck nears $6bn biotech deal to boost cancer drug pipeline

10h later

Reuters25 Mar, 10:51

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma - Reuters

cnbc25 Mar, 11:14

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

marketwatch25 Mar, 11:35

Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal

capital-bg25 Mar, 12:17

Бизнес глобус: OpenAI набира още 10 млрд. долара преди потенциално IPO; Merck преговаря за придобиване на Terns Pharma

wsj25 Mar, 13:14

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns - WSJ

AP25 Mar, 13:39

Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires - AP News

bloomberg25 Mar, 13:43

Merck to Buy Terns for $6.7 Billion to Grow in Blood Cancers - Bloomberg.com

Yahoo25 Mar, 14:41

Merck to acquire Terns Pharmaceuticals for $6.7B

2h later

seeking-alpha25 Mar, 16:31Latest update

Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B

Story evolution

The narrative shifted from initial reports of negotiations and 'nearly $6 billion' to a confirmed acquisition with a more precise $6.7 billion valuation, emphasizing Merck's strategic rationale.

Early Reporting of NegotiationsMarch 25, 00:00 - 12:00 UTC

Initial reports from FT and Capital-BG indicated Merck was nearing or negotiating a deal for Terns, with FT noting Terns' stock jump from prior clinical data.

Confirmation of Acquisition and ValueMarch 25, 10:00 - 12:00 UTC

Reuters, CNBC, MarketWatch, and Seeking Alpha confirmed the acquisition, specifying the $6.7 billion value and highlighting the strategic importance for Merck's cancer portfolio.

Finalization and Market ImpactMarch 25, 13:00 - 15:00 UTC

Later reports from WSJ and Yahoo reiterated the deal, with WSJ still using 'nearly $6 billion' while others solidified the $6.7 billion figure, and Seeking Alpha detailed the per-share price.

Merck Finalizes Nearly $6 Billion Acquisition of Cancer Biotech Terns

Why this matters

The Story

What sources agree on

Key claims3 agreed · 1 disputed · 1 unverified

Coverage gaps

The Story

Source Diversity

Source Diversity

Political spectrum

Sources

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma - Reuters

Merck to Buy Terns for $6.7 Billion to Grow in Blood Cancers - Bloomberg.com

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns - WSJ

Merck nears $6bn biotech deal to boost cancer drug pipeline

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal

Coverage Timeline

Merck nears $6bn biotech deal to boost cancer drug pipeline

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma - Reuters

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal

Бизнес глобус: OpenAI набира още 10 млрд. долара преди потенциално IPO; Merck преговаря за придобиване на Terns Pharma

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns - WSJ

Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires - AP News

Merck to Buy Terns for $6.7 Billion to Grow in Blood Cancers - Bloomberg.com

Merck to acquire Terns Pharmaceuticals for $6.7B

Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B

Story evolution

Related Stories

Wall Street Giant Bets Against Borr Drilling Stock

Heatwaves Impact Work Conditions and Productivity in Czech Republic

Understanding Market Terminology for Investors

Opel Astra Identified as Cheapest Diesel Car in Greece

Why this matters

Story evolution

The Story

What sources agree on

Key claims3 agreed · 1 disputed · 1 unverified

Coverage gaps

Political spectrum

Coverage matrix